PubRank

Jeannine S McCune

Author PubWeight™ 37.26‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest 2010 1.49
2 Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006 1.47
3 Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med 2005 1.27
4 Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. Drug Metab Dispos 2011 1.27
5 Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 2005 1.27
6 A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005 1.23
7 Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care 2010 1.15
8 The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos 2002 1.06
9 Myalgias and arthralgias associated with paclitaxel. Oncology (Williston Park) 2003 1.02
10 Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 2008 0.98
11 A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2005 0.94
12 A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. Cancer Chemother Pharmacol 2008 0.93
13 A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients. Clin Cancer Res 2009 0.93
14 Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. Clin Cancer Res 2006 0.93
15 Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol 2010 0.92
16 Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013 0.92
17 A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells. J Chromatogr B Analyt Technol Biomed Life Sci 2005 0.90
18 Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clin Pharmacol Ther 2005 0.90
19 Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes. Biol Blood Marrow Transplant 2013 0.90
20 Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011 0.88
21 Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration. J Clin Pharmacol 2010 0.88
22 Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006 0.87
23 Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig. Transplantation 2009 0.87
24 A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. J Clin Pharmacol 2011 0.86
25 The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer 2005 0.86
26 Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2012 0.85
27 A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. Cancer Chemother Pharmacol 2013 0.83
28 Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol 2011 0.82
29 Intracellular disposition of fludarabine triphosphate in human natural killer cells. Cancer Chemother Pharmacol 2008 0.81
30 Health care use and primary prophylaxis with colony-stimulating factors. Value Health 2011 0.80
31 High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. Int J Clin Pharmacol Ther 2013 0.80
32 Effects of Garlic on Cytochromes P450 2C9- and 3A4-Mediated Drug Metabolism in Human Hepatocytes. Sci Pharm 2010 0.79
33 Pharmacokinetics of oral mycophenolate mofetil in dog: bioavailability studies and the impact of antibiotic therapy. Biol Blood Marrow Transplant 2006 0.78
34 Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007 0.78
35 Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults. Cancer Chemother Pharmacol 2013 0.78
36 Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing. Eur J Clin Pharmacol 2014 0.77
37 The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemother Pharmacol 2005 0.77
38 Imatinib inhibition of fludarabine uptake in T-lymphocytes. Cancer Chemother Pharmacol 2007 0.76
39 Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother 2006 0.75
40 Predictive performance of a physiologically based pharmacokinetic model of busulfan in children. Pediatr Hematol Oncol 2014 0.75
41 A pilot study of website information regarding aromatase inhibitors: dietary supplement interactions. J Altern Complement Med 2011 0.75
42 A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. Cancer Invest 2005 0.75
43 Topotecan disposition in an anephric child. J Pediatr Hematol Oncol 2004 0.75